- CYTR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $3.7 million.
- CYTR has traded 166,258 shares today.
- CYTR is trading at 2.37 times the normal volume for the stock at this time of day.
- CYTR is trading at a new high 3.12% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in CYTR with the Ticky from Trade-Ideas. See the FREE profile for CYTR NOW at Trade-Ideas More details on CYTR: CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. Currently there are 4 analysts that rate CytRx a buy, no analysts rate it a sell, and 1 rates it a hold. The average volume for CytRx has been 662,400 shares per day over the past 30 days. CytRx has a market cap of $198.1 million and is part of the health care sector and drugs industry. The stock has a beta of 2.39 and a short float of 18.9% with 10.79 days to cover. Shares are up 12.6% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates CytRx as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 66.0% when compared to the same quarter one year ago, falling from -$13.44 million to -$22.30 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, CYTRX CORP's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has decreased to -$13.50 million or 14.48% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
- Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 34.11%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 41.66% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- CYTRX CORP's earnings per share declined by 41.7% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, CYTRX CORP reported poor results of -$0.97 versus -$0.54 in the prior year. This year, the market expects an improvement in earnings (-$0.96 versus -$0.97).
- You can view the full CytRx Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.